Parsvnath Midc Pharma Sez Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 27-05-2024
- Paid Up Capital ₹ 4.99 Cr
as on 27-05-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2019)
- Profit 14.84%
(FY 2019)
- Ebitda 13.73%
(FY 2019)
- Net Worth -0.10%
(FY 2019)
- Total Assets -0.06%
(FY 2019)
About Parsvnath Midc Pharma Sez
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.99 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rahul Srivastav and Surya Pandey serve as directors at the Company.
- CIN/LLPIN
U24239MH2008PTC178174
- Company No.
178174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2008
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Ahmed Nagar, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Parsvnath Midc Pharma Sez?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Srivastav  | Director | 10-Dec-2018 | Current |
| Surya Pandey | Director | 16-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Parsvnath Midc Pharma Sez.
Parsvnath Midc Pharma Sez Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 14.84% increase in profit. The company's net worth dipped by a decrease of 0.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parsvnath Midc Pharma Sez?
In 2018, Parsvnath Midc Pharma Sez had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Parsvnath Rail Land Project Private LimitedActive 13 years 1 month
Rahul Srivastav is a mutual person
- Parsvnath Promoters And Developers Private LimitedActive 17 years 4 months
Rahul Srivastav is a mutual person
- Parsvnath Landmark Developers Private LimitedActive 21 years 2 months
Surya Pandey is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Parsvnath Midc Pharma Sez?
Unlock and access historical data on people associated with Parsvnath Midc Pharma Sez, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parsvnath Midc Pharma Sez, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parsvnath Midc Pharma Sez's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
